 Home > Medical News > Latest Medical News > BeiGene announced to be included in the FTSE Russell Index

BeiGene announced to be included in the FTSE Russell Index

 Last Update: 2021-10-01
 Source: Internet
 Author: User

Tags

chemours stock price

exxon stock

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Cambridge, MA, USA and Beijing, China, September 20, 2021/PRNewswire/ - BeiGene (NASDAQ: BGNE; HKEX: 06160) is a science-based global biotechnology company focused on development, innovation, and affordable The drug is designed to improve the effectiveness of treatment and increase the accessibility of drugs for patients around the world

FTSE Russell (FTSE Russell) is the world's leading index provider, providing global investors with innovative benchmark measurement, analysis tools and data solutions

"BeiGene's inclusion in the FTSE Russell Index can potentially increase the company's visibility in the global investment community and make the overall composition of investors more diverse

The core of BeiGene's environmental, social and corporate governance (ESG) goals is to develop affordable and accessible drugs for more patients around the world; provide employees with opportunities for growth and development; and conduct business in a responsible and sustainable manner

Christine Riley Miller, Head of Reputation and ESG at BeiGene, added: “At BeiGene, our mission is not only to develop the best treatments for patients around the world, but also to create a more inclusive, fair and sustainable world

For more information about BeiGene's ESG work, please refer to the company's first global ESG report

For more information, please refer to the index page on the FTSE Russell website https://

About BeiGene

BeiGene is a global biotechnology company based on science, focusing on the development of innovative and affordable drugs, aiming to improve treatment outcomes and access to drugs for patients around the world

Forward-looking statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including BeiGene’s plans, commitments, visions, and goals, such as A vision to improve the accessibility and affordability of cancer treatments for patients worldwide

Source: BeiGene

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.